At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
LY3493269 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an LY3493269 Formulation in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating LY3493269, Placebo, and 1 other intervention for Healthy. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3493269 in healthy participants. The blood tests will be performed to check how much LY3493269 gets into the bloodstream, how long the body takes to eliminate it and how body handles LY3493269. The study will last up to approximately 71 days for each participant, including screening
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartMay 2021
Primary CompletionNov 2021
TodayJul 2026
First PostedDec 23, 2020
Enrollment StartMay 3, 2021
Primary CompletionNov 11, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.5 years ago
Interventions
LY3493269drug
Administered orally.
Placebodrug
Administered orally.
Salcaprozate Sodiumdrug
Administered orally.